Anecortave Acetate Risk Reduction Trial (AART)

The purpose of this study is to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of dry age-related macular degeneration (AMD) in patients who are at-risk for progressing to wet AMD.

Inclusion Criteria:

• Dry AMD in study eye, Wet AMD non-study eye.
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Under 50.
• Other protocol-defined exclusion criteria may apply.